CONTEXT AND OBJECTIVE: Given that Brazil has a universal public policy for supplying medications to treat HIV and AIDS, the aim here was to describe the forms of relationship between physicians and the pharmaceutical companies that produce antiretrovirals (ARVs). DESIGN AND SETTING: Cross-sectional epidemiological study conducted in the state of São Paulo. METHODS: Secondary database linkage was used, with structured interviews conducted by telephone among a sample group of 300 physicians representing 2,361 professionals who care for patients with HIV and AIDS. RESULTS: Around two thirds (64%) of the physicians prescribing ARVs for HIV and AIDS treatment in the state of São Paulo who were interviewed declared that they had some form of relationship with pharmaceutical companies, of which the most frequent were receipt of publications (54%), visits by sales promoters (51%) and receipt of small-value objects (47%). CONCLUSIONS: Two forms of relationship between the pharmaceutical industry and physicians who deal with HIV and AIDS can be highlighted: facilitation of professionals' access to continuing education; and antiretroviral drug brand name promotion.
INTRODUCTION
The AIDS epidemic introduced new elements into the world of drug research and development. It gave rise to unprecedented behavior within the pharmaceutical industry, the fields of medicine and science, the ethics of human research and the organization of services and community mobilization to ensure access to antiretroviral therapy. 1 In the early 1990s, monotherapy with antiretrovirals (ARVs), followed by combinations of two medications, offered patients modest and ephemeral benefits before the disease evolved. The therapeutic approach to AIDS made unquestionable progress only after the introduction, in 1995, of highly active antiretroviral therapy (HAART), which featured protease inhibitor drugs, thus making ARV combinations more powerful and effective. The role of ARV drugs is to inhibit viral replication, restore the immune system of infected people and reduce occurrences of opportunistic infections and other morbidities. 2 The pharmaceutical companies responsible for discovering and launching ARVs form one of the most competitive sectors of the global market, dominated by multinational corporations.
They are large companies capable of financing and incorporating into their products the main advances that are seen to be possible within the biomedical, biological and chemical sciences. patients each. On average, the physicians cared for six patients with HIV and AIDS per day, whereas 75% cared for between one and ten patients on a daily basis. Out of the total number sampled, 11% declared that they were not regular prescribers, since they had seldom prescribed ARVs.
Among the doctors who cared for patients with HIV and AIDS in the state of São Paulo, 64% declared that they had received products, benefits or payments from the pharmaceutical laboratories that produce ARVs (Figure 1) .
The most common benefits received ( Figure 2) were: informative materials about ARVs (54%); visits by sales promoters and sales representatives (51%); inexpensive objects for the doctor's office (47%); invitations to take part in continuing education courses and events (40%); and scientific journals sponsored by the laboratories (38%). In smaller proportions, the physicians declared the following benefits: lunches or dinners (27%); trips to national conventions (17%) and international conventions (7%); invitations to take part in or to conduct clinical research (15%); tickets to cultural and leisure events (11%); fees relating to consulting services, lessons, lectures or speaking at conventions (5%); and free
ARV drug samples (1%).
With regard to the benefits offered, infectologists (or specialists in infectious diseases) were the physicians who most received small-value objects (P < 0.001) and trips to national conventions (P = 0.021). This statistical significance was obtained through contingency table analysis using the chisquare test (x 2 ) and Fisher's exact test, with the significance level of α < 0.05. 8 In relation to other benefits, although high numbers were received by the infectologists, statistical significance was not observed (Annex). 
DISCUSSION
This study shows that one of the strategies of the ARV industry is to invest in training and information for physicians, which includes sponsorship of courses and production of informative material. Another initiative is financial support for physicians' participation in scientific events and congresses, where the pharmaceutical companies take part in scheduling and organizing satellite events, erect stands and develop promotional activities.
However, it is worth emphasizing that this study shows that only a minority of the physicians who were prescribing ARVs (10%) affirmed that the companies exerted considerable influence over them.
Although the percentage of physicians who prescribed ARVs (64%) and had received some benefit from the industry was lower than the level that has been identified in other studies evaluating the relationship between physicians and the industry. In the state of São Paulo, 93% of physicians in general were found to have received some benefit from pharmaceutical, equipment, orthosis and prosthesis companies. 9 In the United States, 94% of physicians were found to have some connection with drug manufacturers. 
